| Title |
A Phase I/II, Open Label, Multicenter Study to Assess Safety and Anti-tumor Efficacy of DZD8586 in Patients with B-NHL |
| Description |
The study consists of two parts: part A, the dose escalation phase that aims to establish RP2D, and part B, the dose expansion phase that includes six cohorts. The primary objective of the study is to define RP2D, evaluate anti-tumor efficacy, safety and tolerability. |
| Organism |
Homo sapiens |
| Data Type |
Other Type of Metabolome Data |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA012477 |
| Release Date |
2024-10-25 |
| Submitter |
Yuqin Song (SongYQ_VIP@163.com) |
| Organization |
Peking University Cancer Hospital & Institute |
| Submission Date |
2022-10-25 |